What is the price target for ATOS stock?
10 analysts have analysed ATOS and the average price target is 44.63 USD. This implies a price increase of 650% is expected in the next year compared to the current price of 5.95.
NASDAQ:ATOS • US04962H7044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATOSSA THERAPEUTICS INC (ATOS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-10 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2026-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-08 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-09-22 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-05 | Craig-Hallum | Initiate | Buy |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-11 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-05-14 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 1,307.08% | N/A 74.64% | N/A 71.87% | N/A -79.27% | N/A 57.95% | ||||||||||||
| EBITDA YoY % growth | -12.49M | -6.95M 44.36% | -7.06M -1.58% | -11.39M -61.33% | -17.22M -51.19% | -14.56M 15.45% | -20.5M -40.80% | -27.68M -35.02% | -31.354M -13.27% | -27.604M 11.96% | -37.125M -34.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.76M | -7.25M 43.18% | -7.19M 0.83% | -11.43M -58.97% | -17.27M -51.09% | -14.61M 15.40% | -20.52M -40.45% | -27.69M -34.94% | -31.377M -13.32% | -27.621M 11.97% | -37.141M -34.47% | N/A -6.61% | N/A -31.83% | N/A 99.13% | N/A 17,239.46% | N/A 91.31% | N/A 79.89% | N/A -116.76% | N/A 68.18% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 64.31% | N/A 64.40% | -71.25 57.59% | N/A 56.41% | -29.55 4.86% | -2.70 90.86% | -3.15 -16.67% | -4.05 -28.57% | -3.15 22.22% | -5.93 -88.25% | N/A 24.49% | N/A 35.54% | N/A -9.72% | N/A -126.41% | N/A 99.15% | N/A 7,066.67% | N/A -38.52% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -6.32 -743.20% | -1.10 -4.91% | -1.21 -15.11% | -1.16 62.25% | -1.19 81.13% | -1.29 -16.67% | -1.38 -13.92% | -1.50 -28.95% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -9.503M -28.18% | -10.073M -11.42% | -10.634M -14.94% | -11.195M 2.11% | -10.71M -12.70% | -11.475M -13.92% | -12.24M -15.11% | -13.26M -18.45% |
All data in USD
10 analysts have analysed ATOS and the average price target is 44.63 USD. This implies a price increase of 650% is expected in the next year compared to the current price of 5.95.
ATOSSA THERAPEUTICS INC (ATOS) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of ATOSSA THERAPEUTICS INC (ATOS) is -6.32 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering ATOSSA THERAPEUTICS INC (ATOS) is 10.